Clinical trials: Maximum Tolerated Dose
Cancer
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
The purpose of this study is to determine the safety and pharmacokinetics of TAK-285 in patients with advanced cancer.
- Trial name
- NCT00535522
- Testing
- TAK-285 Dose Escalation Cohorts, TAK-285 Recommended Phase 2 Dosing Cohort
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
The aim of this study is to determine the maximal tolerated dose level of lenalidomide combined with fludarabine/rituximab in the therapy of patients with previously untreated CD20-positive chronic lymphocytic leukemia.
- Trial name
- NCT00738829
- Testing
- Lenalidomide, Fludarabine, Rituximab
- Where
- 7 sites in Austria
- Volunteers
- 45 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Momelotinib During and After HCT in Myelofibrosis
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
- Trial name
- NCT07104799
- Testing
- Momelotinib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Leukemia, Myeloid, Acute
A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)
Phase I Dose Escalation: Primary objective is to determine the Maximum Tolerated Dose (MTD) and the recommended dose for Phase I Extension.
- Trial name
- NCT02632721
- Testing
- Decitabine, BI 836858
- Where
- 14 sites in United States, Germany and 2 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
The main objective of this study is to determine the maximum tolerated dose (MTD) of HM781-36B.
- Trial name
- NCT01455571
- Testing
- HM781-36B
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-Small-Cell Lung Carcinoma
Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer
The purpose of this study is to establish the safest dose of the investigational medication Belinostat that can be administered with a standard of care chemotherapy regimen of bevacizumab, carboplatin, and paclitaxel.
- Trial name
- HCH003 (NCT01090830)
- Testing
- Belinostat, carboplatin, paclitaxel and bevacizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Holy Cross Hospital, Florida
Relapsed or Refractory Multiple Myeloma
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose.
- Trial name
- NCT00708292
- Testing
- AUY922, Bortezomib, Dexamethasone
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumours
A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours
The purpose of this study is to determine the maximum tolerated dose of the oral Src/Abl inhibitor AZD0424, and to find tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours
- Trial name
- AZD0424 (NCT01668550)
- Testing
- AZD0424
- Where
- 3 sites in United Kingdom
- Volunteers
- 43 people
- Sponsor
- Cancer Research UK
Solid Tumors, Soft-tissue Sarcoma
A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
Assessment of the efficacy and safety of JX-594 and metronomic cyclophosphamide in patients with advanced soft-tissue sarcoma and advanced breast cancer, once the Maximum Tolerated Dose have been determined (phase I trial).
- Conditions
- Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
- Trial name
- METROmaJX (NCT02630368)
- Testing
- Cyclophosphamide and JX-594 dose escalation, Cyclophosphamide and JX-594, Cyclophosphamide
- Where
- France
- Volunteers
- 197 people
- Sponsor
- Institut Bergonié
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphoproliferative Diseases
Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease.
- Trial name
- NCT00124189
- Testing
- GRN163L
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Geron Corporation
Neoplasm
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms
P276-00 is specific Cdk4-D1 and Cdk1-B inhibitor. P276-00 exhibited significant tumour reduction in animal models with less adverse effects.Based on the results from various in-vitro studies, P276-00 could be a potential…
- Trial name
- NCT00407498
- Testing
- P276-00
- Where
- 3 sites in Canada, India
- Volunteers
- 50 people
- Sponsor
- Piramal Enterprises Limited
HPV-Related Carcinoma
IBRX-042 In Participants With HPV-Associated Tumors
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV)…
- Trial name
- NCT05976828
- Testing
- IBRX-042
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- ImmunityBio, Inc.
Leukemia
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
- Trial name
- NCT01029509
- Testing
- OPB 31121
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors, Lymphoma
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of AP23573 in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060645
- Testing
- ridaforolimus
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Gastric Carcinoma
Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma
The purpose of this study is to determine the maximum tolerated dose and dose limiting toxicity of liposomal paclitaxel plus capecitabine in Chinese patients with advanced gastric carcinoma.
- Trial name
- NCT00881816
- Testing
- Liposomal paclitaxel plus capecitabine
- Volunteers
- 15 people
- Sponsor
- Nanjing Sike Pharmaceutical Co., Ltd.
Safety, Pharmacokinetics
Pentoxifylline PKB171 Gel in Healthy Females Volunteers
A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Trial to evaluate the Safety and Tolerability of Pentoxifylline PKB171 Gel in Single-Dose Intravaginal Administration, followed by an Extension…
- Conditions
- Safety, Pharmacokinetics, Maximum Tolerated Dose
- Trial name
- NCT07017114
- Testing
- Gel PKB171
- Volunteers
- 30 people
- Sponsor
- Prokrea BCN, S.L.
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Multiple Myeloma
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) of pomalidomide in combination with bortezomib and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma
- Trial name
- NCT01497093
- Testing
- Pomalidomide, Bortezomib, Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Celgene
Prostatic Neoplasms
First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer
This is the first study where BAY2010112 is given to humans. Patients with castration resistant prostate cancer will be treated. Every patient will receive drug treatment, there is no placebo group.
- Trial name
- NCT01723475
- Testing
- BAY2010112
- Where
- 5 sites in Austria, Germany
- Volunteers
- 47 people
- Sponsor
- Bayer